Julphar Gulf Pharmaceutical Industries announced today revenues of AED992 million for the first three quarters of the year 2017. The company posted an AED86 million net profit for the period.
"Overall, the MENA markets remained challenging for the pharmaceutical industry. Julphar’s management has undertaken cost-saving initiatives and new projects to optimise processes further and consolidate our current market shares. We will continue to launch our new products pipeline while increasing our geographical presence, to fully align towards with our 2020 roadmap," said Jerome Carle, Julphar General Manager.
"Saudi Arabia remains the major revenue contributor for Julphar, despite the current market situation in the Kingdom. At the same time, the UAE operations achieved a solid growth of 16 percent. With steady double-digit growth, the performance of the North African and Levant regions confirms Julphar as a strategic player in the area."
GMT 19:26 2018 Friday ,19 January
True healthcare innovation is behind the scenesGMT 19:14 2018 Friday ,19 January
DHA to incorporate unified immunisation recordsGMT 17:50 2018 Friday ,19 January
Emirates Healthcare launches Al Reef Medical CentreGMT 17:46 2018 Friday ,19 January
Ministerial Development Council reviews National StrategyGMT 19:36 2018 Thursday ,18 January
DHA to incorporate unified immunisation recordsMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Send your comments
Your comment as a visitor